Articles Tagged With: isoniazid
-
Rifampin vs. Isoniazid for Latent Tuberculosis
A health system cost comparison showed that four months of rifampin was safer and less expensive than nine months of isoniazid in high-income countries, medium-income countries, and African countries.
-
2020 Updated LTBI Treatment Guidelines
A committee recommended three rifamycin-based regimens and two alternate six- or nine-month isoniazid monotherapy regimens for latent tuberculosis infection treatment. They gave priority to shorter-course regimens with similar efficacy, higher rates of completion, and favorable tolerability compared with the former standard nine-month regimen of isoniazid.
-
Latent Tuberculosis Treatment With Four Months of Rifampin Compared to Nine Months of Isoniazid
In an open-label trial, adults with latent tuberculosis infection were randomized to either four months of treatment with rifampin or nine months of treatment with isoniazid. The four-month rifampin regimen was non-inferior to nine months of isoniazid for prevention of active tuberculosis. It also was associated with a higher treatment completion rate and superior safety.
-
Screening for Latent Tuberculosis: An Update After 20 Years
Detection and treatment of latent tuberculous infection remains a key element of tuberculosis control in the United States.
-
Preventing Active Tuberculosis in Children
A three-month course of weekly rifapentine and isoniazid is safe and at least as effective as nine months of daily isoniazid in preventing tuberculosis in children aged 2 to 17 years.